{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:32:40Z","timestamp":1790195560673,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800752"],"award-info":[{"award-number":["81800752"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20170125"],"award-info":[{"award-number":["BK20170125"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Key Medical Discipline","award":["ZDXKB2016012"],"award-info":[{"award-number":["ZDXKB2016012"]}]},{"name":"Key Research and Development Program of Jiangsu Province of China","award":["BE2015604"],"award-info":[{"award-number":["BE2015604"]}]},{"name":"Key Research and Development Program of Jiangsu Province of China","award":["BE2016606"],"award-info":[{"award-number":["BE2016606"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0246-x","type":"journal-article","created":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T09:12:33Z","timestamp":1537175553000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis"],"prefix":"10.1186","volume":"19","author":[{"given":"Xiaowen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalong","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-7854","authenticated-orcid":false,"given":"Yan","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"key":"246_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"E Di Angelantonio","year":"2015","unstructured":"Di Angelantonio E, Kaptoge S, Wormser D, Willeit P, Butterworth AS, Bansal N, et al. Association of cardiometabolic multimorbidity with mortality. JAMA. 2015;314:52\u201360.","journal-title":"JAMA"},{"key":"246_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1006524","volume":"364","author":"HC Gerstein","year":"2011","unstructured":"Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DJ, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364:818\u201328.","journal-title":"N Engl J Med"},{"key":"246_CR3","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMicm066227","volume":"358","author":"A Patel","year":"2008","unstructured":"Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560\u201372.","journal-title":"N Engl J Med"},{"key":"246_CR4","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1016\/S0140-6736(14)61402-1","volume":"385","author":"RE Gilbert","year":"2015","unstructured":"Gilbert RE, Krum H. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet. 2015;385:2107\u201317.","journal-title":"Lancet"},{"key":"246_CR5","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"246_CR6","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.2337\/dc07-0141","volume":"30","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care. 2007;30:2148\u201353.","journal-title":"Diabetes Care"},{"key":"246_CR7","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(14)60794-7","volume":"383","author":"RR Holman","year":"2014","unstructured":"Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. Lancet. 2014;383:2008\u201317.","journal-title":"Lancet"},{"key":"246_CR8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1056\/NEJMp0805758","volume":"359","author":"AB Goldfine","year":"2008","unstructured":"Goldfine AB. Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008;359:1092\u20135.","journal-title":"N Engl J Med"},{"key":"246_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jacc.2015.12.058","volume":"67","author":"G Waldrop","year":"2016","unstructured":"Waldrop G, Zhong J, Peters M, Rajagopalan S. Incretin-based therapy for diabetes. what a cardiologist needs to know J Am Coll Cardiol. 2016;67:1488\u201396.","journal-title":"what a cardiologist needs to know J Am Coll Cardiol"},{"key":"246_CR10","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00125-011-2447-3","volume":"55","author":"B Eliasson","year":"2012","unstructured":"Eliasson B, Moller-Goede D, Eeg-Olofsson K, Wilson C, Cederholm J, Fleck P, Diamant M, Taskinen MR, Smith U. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and\/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55:915\u201325.","journal-title":"Diabetologia"},{"key":"246_CR11","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.1016\/S0140-6736(14)61335-0","volume":"384","author":"C Eng","year":"2014","unstructured":"Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet. 2014;384:2228\u201334.","journal-title":"Lancet"},{"key":"246_CR12","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","volume":"151","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264\u20139. W64","journal-title":"Ann Intern Med"},{"key":"246_CR13","unstructured":"Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. \n                    http:\/\/handbook-5-1.cochrane.org\/\n                    \n                  . Accessed 28 Sept 2017."},{"key":"246_CR14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"246_CR15","first-page":"719","volume":"22","author":"N Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719\u201348.","journal-title":"J Natl Cancer Inst"},{"key":"246_CR16","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jclinepi.2007.03.013","volume":"61","author":"J Wetterslev","year":"2008","unstructured":"Wetterslev J, Thorlund K, Brok J, Gluud C. Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis. J Clin Epidemiol. 2008;61:64\u201375.","journal-title":"J Clin Epidemiol"},{"key":"246_CR17","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/S0197-2456(97)00051-2","volume":"18","author":"JM Pogue","year":"1997","unstructured":"Pogue JM, Yusuf S. Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. Control Clin Trials. 1997;18:580\u201393.","journal-title":"Control Clin Trials"},{"key":"246_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/ije\/dyn188","volume":"38","author":"J Brok","year":"2009","unstructured":"Brok J, Thorlund K, Wetterslev J, Gluud C. Apparently conclusive meta-analyses may be inconclusive--trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses. Int J Epidemiol. 2009;38:287\u201398.","journal-title":"Int J Epidemiol"},{"key":"246_CR19","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"246_CR20","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"issue":"19","key":"246_CR21","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"Steven P. Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;(19):1834\u201344.","journal-title":"New England Journal of Medicine"},{"key":"246_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med"},{"key":"246_CR23","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.ijcard.2016.07.199","volume":"222","author":"S Ding","year":"2016","unstructured":"Ding S, Du YP, Lin N, Su YY, Yang F, Kong LC, Ge H, Pu J, He B. Effect of glucagon-like peptide-1 on major cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Int J Cardiol. 2016;222:957\u201362.","journal-title":"Int J Cardiol"},{"key":"246_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/dom.12175","volume":"16","author":"M Monami","year":"2014","unstructured":"Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16:38\u201347.","journal-title":"Diabetes Obes Metab"},{"key":"246_CR25","doi-asserted-by":"publisher","first-page":"j2499","DOI":"10.1136\/bmj.j2499","volume":"357","author":"J Liu","year":"2017","unstructured":"Liu J, Li L, Deng K, Xu C, Busse JW, Vandvik PO, Li S, Guyatt GH, Sun X. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis. BMJ. 2017;357:j2499.","journal-title":"BMJ"},{"key":"246_CR26","unstructured":"US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: diabetes mellitus\u2014 evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Available: \n                    https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071627.pdf\n                    \n                  . Accessed 28 Sept 2017."},{"key":"246_CR27","doi-asserted-by":"crossref","unstructured":"Li L, Li S, Deng K, Liu J, Vandvik PO, Zhao P, et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ. 2016:i610.","DOI":"10.1136\/bmj.i610"},{"key":"246_CR28","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317\u201326.","journal-title":"N Engl J Med"},{"key":"246_CR29","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/S2213-8587(14)70031-2","volume":"2","author":"JJ McMurray","year":"2014","unstructured":"McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843\u201351.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"246_CR30","unstructured":"O'Gara PT, Kushner FG, Ascheim DD, Casey DJ, Chung MK, de Lemos JA, et al: 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. J Am Coll Cardiol 2013;61:e78\u2013140."},{"key":"246_CR31","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht310.P4876","volume":"34","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J"},{"issue":"16","key":"246_CR32","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"Paul M Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;(16):1527\u201339.","journal-title":"New England Journal of Medicine"},{"issue":"18","key":"246_CR33","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Marc S. Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;(18):1713\u201322.","journal-title":"New England Journal of Medicine"},{"key":"246_CR34","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"246_CR35","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"issue":"7","key":"246_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"Bruce Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;(7):644\u201357.","journal-title":"New England Journal of Medicine"},{"key":"246_CR37","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327\u201335.","journal-title":"N Engl J Med"},{"key":"246_CR38","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373:232\u201342.","journal-title":"N Engl J Med"},{"key":"246_CR39","doi-asserted-by":"crossref","unstructured":"Standards of Medical Care in Diabetes\u20142018. Diabetes Care. 2018;Supplement 1:S1\u2013155.","DOI":"10.2337\/dc18-Sint01"},{"key":"246_CR40","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","volume":"136","author":"MA Nauck","year":"2017","unstructured":"Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136:849\u201370.","journal-title":"Circulation"},{"key":"246_CR41","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1007\/s00125-015-3632-6","volume":"58","author":"G Xu","year":"2015","unstructured":"Xu G, Li Z, Ding L, Tang H, Guo S, Liang H, Wang H, Zhang W. Intestinal mTOR regulates GLP-1 production in mouse L cells. Diabetologia. 2015;58:1887\u201397.","journal-title":"Diabetologia"},{"key":"246_CR42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3109\/07853890.2013.770333","volume":"45","author":"G Tarantino","year":"2013","unstructured":"Tarantino G, Capone D. Inhibition of the mTOR pathway: a possible protective role in coronary artery disease. Ann Med. 2013;45:348\u201356.","journal-title":"Ann Med"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0246-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0246-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,21]],"date-time":"2019-09-21T07:36:34Z","timestamp":1569051394000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0246-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["246"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0246-x","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"24 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"58"}}